Stock VVY VIVORYON THERAPEUTICS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:27 2024-04-26 am EDT 		5-day change 1st Jan Change
0.8 EUR -2.44% Intraday chart for Vivoryon Therapeutics N.V. +76.60% -90.17%
Apr. 24 Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15 Vivoryon Therapeutics N.V Announces Resignation of Board of Directors CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
PU
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
GL
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
AQ
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
GL
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Announces Changes to Board Composition
PU
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
GL
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
AQ
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
PU
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
GL
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
AQ
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
GL
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
AQ
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
GL
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
AQ
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
GL
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
GL
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
GL
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
AQ
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
GL
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VVY Stock
  4. News Vivoryon Therapeutics N.V.
  5. Press Releases